Physician profile
Martin G Roach
NPI 1043316466
$664.26
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $243 · 2021: $223 · 2022: $120 · 2023: $63.29 · 2024: $14.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $77.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $77.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $121.53 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $110.39 | 2020-2024 | Farxiga |
| Pfizer INC. | $98.73 | 2020-2022 | |
| Adlon Therapeutics L.P. | $47.63 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $46.39 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $40.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $29.34 | 2022 | |
| Glaxosmithkline, LLC. | $28.80 | 2021 | |
| Exact Sciences Corporation | $27.15 | 2023 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $24.80 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.12 | 2020 | |
| Janssen Biotech, INC. | $19.01 | 2023 | Tremfya |
| Amgen INC. | $17.13 | 2023 | Repatha |
| Eisai INC. | $17.10 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.